Clinical Trial Update: A Phase II Study Comparing Pegylated rhG-CSF（HHPG-19K） and rhG-CSF in Breast Cancer Patients Receiving Chemotherapy [Phase 2]

View source ↗

Summary

A Phase II trial evaluating pegylated rhG-CSF (HHPG-19K) versus rhG-CSF in breast cancer patients receiving chemotherapy has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Pegylated rhG-CSF (HHPG-19K) (pegylated recombinant human granulocyte colony-stimulating factor)
• rhG-CSF (recombinant human granulocyte colony-stimulating factor)

Snippet

Sponsor: Jiangsu HengRui Medicine Co., Ltd. | Conditions: Breast Cancer, Neutropenia | Phase 2 | Status: COMPLETED